Headlands Technologies LLC Invests $1.16 Million in Kiniksa Pharmaceuticals International, plc $KNSA

Headlands Technologies LLC acquired a new position in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) in the second quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 18,161 shares of the company’s stock, valued at approximately $1,161,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of KNSA. Qube Research & Technologies Ltd increased its stake in Kiniksa Pharmaceuticals International by 277.8% in the second quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock valued at $24,581,000 after purchasing an additional 653,236 shares during the last quarter. Rubric Capital Management LP lifted its holdings in shares of Kiniksa Pharmaceuticals International by 15.6% in the second quarter. Rubric Capital Management LP now owns 3,909,806 shares of the company’s stock valued at $108,184,000 after purchasing an additional 526,567 shares in the last quarter. Bank of America Corp DE increased its position in Kiniksa Pharmaceuticals International by 220.9% during the first quarter. Bank of America Corp DE now owns 735,940 shares of the company’s stock worth $35,436,000 after buying an additional 506,576 shares in the last quarter. Cubist Systematic Strategies LLC boosted its stake in shares of Kiniksa Pharmaceuticals International by 213.2% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 657,475 shares of the company’s stock worth $18,192,000 after purchasing an additional 447,536 shares during the last quarter. Finally, Spruce Street Capital LP acquired a new position in Kiniksa Pharmaceuticals International in the 4th quarter valued at $17,943,000. 53.95% of the stock is currently owned by hedge funds and other institutional investors.

Kiniksa Pharmaceuticals International Stock Up 0.7%

Shares of Kiniksa Pharmaceuticals International stock opened at $78.63 on Tuesday. Kiniksa Pharmaceuticals International, plc has a 12-month low of $33.25 and a 12-month high of $82.94. The firm has a market capitalization of $6.13 billion, a PE ratio of 81.06 and a beta of 0.05. The stock’s fifty day moving average is $70.32 and its 200-day moving average is $56.48.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its earnings results on Tuesday, July 28th. The company reported $0.30 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.30. The company had revenue of $243.60 million for the quarter, compared to the consensus estimate of $226.49 million. Kiniksa Pharmaceuticals International had a net margin of 9.59% and a return on equity of 13.65%. Analysts expect that Kiniksa Pharmaceuticals International, plc will post 1.37 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on KNSA. Weiss Ratings downgraded shares of Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, August 13th. Wall Street Zen downgraded Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research note on Sunday, July 12th. Canaccord Genuity Group raised their price objective on Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. JPMorgan Chase & Co. boosted their price objective on Kiniksa Pharmaceuticals International from $72.00 to $107.00 and gave the company an “overweight” rating in a research report on Wednesday, July 29th. Finally, The Goldman Sachs Group boosted their price objective on Kiniksa Pharmaceuticals International from $75.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. Eight investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $87.38.

Insider Transactions at Kiniksa Pharmaceuticals International

In related news, Director G Bradley Cole sold 3,673 shares of the company’s stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $81.43, for a total value of $299,092.39. Following the completion of the sale, the director directly owned 11,672 shares in the company, valued at approximately $950,450.96. This represents a 23.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 51.98% of the company’s stock.

Kiniksa Pharmaceuticals International Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.